[ A24-72] Osimertinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2024
Project no.:
A24-72
Commission:
Commission awarded on 28.06.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adjuvant treatment after complete tumour resection in adult patients with stage IB to IIIA non-small cell lung cancer whose tumours have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations
- Patients for whom adjuvant platinum-based chemotherapy is suitable: added benefit not proven
- Patients after prior adjuvant platinum-based chemotherapy or for whom this therapy it is not suitable: hint of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-72_en
| Project no. | Title | Status |
|---|---|---|
| A21-86 | Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-45 | Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-20 | Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-14 | Osimertinib - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-77 | Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Benefit assessment according to §35a Social Code Book V | Commission completed |